Microba Life Sciences Ltd has released a press release.
Research Agreement Executed with IFF for Allergy Program
Filed with ASX ·
Watch Microba Life Sciences' latest callMicroba Life Sciences (ASX:MAP) Q4 2025 Earnings Call · Replay · Jul 22, 2025Read the transcript of Microba Life Sciences (ASX:MAP) Q4 2025 Earnings Call6ix hasn’t read this filing yet.
Microba Life Sciences Limited on 6ix
Story so far
Earlier from Microba Life Sciences
- Autoimmune Stage 1 Screening Complete with Gingko Bioworks
- Results of Retail Entitlement Offer
- Fully Underwritten A$20 million Entitlement Offer
- Invivo Clinical Acquisition and Capital Raising Presentation
- Microba to acquire UK microbiome leader Invivo Clinical
Later from Microba Life Sciences
- Successful IBD Phase I Clinical Trial
- Q2 FY24 Quarterly Activities Report & Appendix 4C
- Q2 FY24 Quarterly Investor Presentation
- Appendix 4D & FY24 Interim Report
- MetaPanel Diagnostic Test Launched with Sonic Healthcare
Follow Microba Life Sciences into a list and get an email when it puts out news.
Follow Microba Life Sciences